


PRESENTER: Andressa Braga,
 Instituto Nacional de Cardiologia. Rio de Janeiro, Brazil

Cost-effectiveness analysis of Liposomal amphotericin B versus Isavuconazole for treating mucormycosis in the consolidation phase from the perspective of the Brazilian Unified Health System

| Item | Estimation point | Lower Limit | Upper Limit | Distribution function | Author |
|---|------------------|-------------|-------------|-----------------------|--|
| Probability of dying with isavuconazole | 0,10 | 0,07 | 0,43 | Beta | Marty et al 2016 / Thompson et al 2021 |
| Probability of dying with amp B ¹ | 0,10 | 0,07 | 0,43 | Beta | Marty et al 2016 / Thompson et al 2021 |
| Probability of responding to isavuconazole | 0,50 | 0,32 | 0,68 | Beta | Seidel, 2020 |
| Probability of responding to amp B ¹ | 0,51 | 0,38 | 0,63 | Beta | Seidel, 2020 |
| Probability of dialysis with Amp B ¹ | 0,05 | 0,03 | 0,06 | Beta | Specialist |
| Probability of responding to Amp B ¹ if failure with the first consolidation treatment | 0,51 | 0,38 | 0,63 | Beta | Lantierier 2015 |
| Probability of dying if treatment failure | 0,32 | 0,26 | 0,38 | Beta | Specialist |
| Isavuconazole cost | 107120,78 | 85696,62 | 128544,93 | gamma | Calc. |
| Amp B ¹ Cost | 784666,85 | 667664,10 | 901669,59 | gamma | Calc. |
| Inpatient Cost | 85880,93 | 68704,74 | 103057,11 | gamma | SIGTAP |
| Outpatient cost | 252,00 | 168,00 | 336,00 | gamma | SIGTAP |
| Cost of not responding to Amp B ¹ | 1131682,99 | 905346,39 | 1358019,58 | gamma | Calc. |
| Cost of not responding to isavuconazole | 927052,89 | 741642,32 | 1112463,47 | gamma | Calc. |
| Cost of dialysis | 53506,66 | 42805,32 | 64207,99 | gamma | SIGTAP |
| Cost of death with isavuconazole | 53560,39 | 42848,31 | 64272,47 | gamma | SIGTAP |
| Cost of death with Amp B ¹ | 392333,42 | 313866,74 | 470800,11 | gamma | SIGTAP |
| Cost of death after second treatment failure (isavuconazole) | 79013,58 | 63210,87 | 94816,30 | gamma | SIGTAP |
| Cost of death after second treatment failure (amp B ¹) | 96050,27 | 76840,22 | 115260,32 | gamma | SIGTAP |
| Cost of dialysis after failure with isavuconazole | 53506,66 | 42805,32 | 64207,99 | gamma | SIGTAP |
| Utility with treatment failure without dialysis | 0,62 | 0,57 | 0,67 | beta | Castejón et al 2018 |
| Utility with treatment failure without dialysis | 0,40 | 0,35 | 0,45 | beta | Stein et al 2018 |
| Utility with dialysis | 0,54 | 0,46 | 0,61 | beta | Liem et al 2008 |
| Utility without dialysis | 0,39 | 0,34 | 0,45 | beta | Calc. |
| Utility of death | 0,00 | NA | NA | NA | |

¹Amp B - Liposomal Amphotericin B

Braga, A; Santos, M; Dias, Q; Mateus, I



Decision tree model

| Treatment | Costs | Utility | Incremental Cost | Incremental Effectiveness | ICER |
|--------------------------|----------------|---------|------------------|---------------------------|----------------------------|
| Liposomal Amphotericin B | R\$ 895.089,03 | 0,479 | | | |
| Isavuconazole | R\$ 490.578,44 | 0,480 | R\$ -404.510,59 | 0,0008 | R\$ -519.942.531,58 / QALY |



Take a picture to
download the full analysis

